
样式: 排序: IF: - GO 导出 标记为已读
-
Altered gut microbiome, bile acid composition and metabolome in sarcopenia in liver cirrhosis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-28 Benard Aliwa, Angela Horvath, Julia Traub, Nicole Feldbacher, Hansjörg Habisch, Günter Fauler, Tobias Madl, Vanessa Stadlbauer
Sarcopenia in liver cirrhosis is associated with low quality of life and high mortality risk. The pathogenesis has yet to be fully understood. We hypothesized that gut microbiome, bile acid (BA) composition and metabolites differ between cirrhotic patients with and without sarcopenia and contribute to pathogenesis.
-
Comment on ‘Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a systematic review and meta-analysis’ J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-27 Fan Zhang, Huachun Zhang
We read the article with great interest published in Journal of Cachexia Sarcopenia and Muscle by Shu et al.1 This systematic review and meta-analysis demonstrated that the prevalence of sarcopenia in dialysis patients was approximately 28.5% (95% CI 22.9–34.1%) and was not associated with mean age (regression coefficient 0.004; 95% CI: −0.005–0.012) and dialysis duration (regression coefficient 0
-
Non-steroidal anti-inflammatory drugs for treatment of cancer cachexia: A systematic review J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-26 Megan Bowers, Brittany Cucchiaro, Joanne Reid, Adrian Slee
Cancer cachexia (CC) is a multifactorial syndrome driven by inflammation, defined by ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support. CC leads to progressive functional impairment, with its clinical management complicated and limited therapeutic options available. The objective of this review was to assess the
-
Impact of sarcopenia on the survival of patients undergoing liver transplantation for decompensated liver cirrhosis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-21 Da Zhou, Donghua Zhang, Chenghao Zeng, Li Zhang, Xuejin Gao, Xinying Wang
Patients with decompensated cirrhosis (DC) are prone to skeletal muscle loss, namely, sarcopenia, before liver transplantation (LT). While sarcopenia is reportedly associated with adverse outcomes after LT, these findings are limited owing to mixed diseases and retrospective data. We investigated the association between sarcopenia and 1-year overall survival (OS) in patients with DC after LT and established
-
Comment on: ‘Triceps skinfold-albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al. - the authors reply J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-21 Liangyu Yin, Jiuwei Cui, Xin Lin, Long Li, Na Li, Yang Fan, Ling Zhang, Jie Liu, Feifei Chong, Zongliang Lu, Chang Wang, Tingting Liang, Xiangliang Liu, Li Deng, Mei Yang, Jiami Yu, Xiaojie Wang, Minghua Cong, Zengning Li, Min Weng, Qinghua Yao, Pingping Jia, Zengqing Guo, Wei Li, Chunhua Song, Hanping Shi, Hongxia Xu
We would like to express our sincere gratitude for the valuable comments and interesting findings by Ding et al.1 regarding the triceps skinfold-albumin index (TA) proposed in our research article.2 Based on data from multiple cohorts of locally advanced gastric cancer (LAGC), the authors found that a higher TA was associated with prolonged overall survival (OS) and disease-free survival (DFS) in LAGC
-
Apples to apples? Discordant definitions still hinder evidence-based treatments for sarcopenia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-21 Giulia Coletta, Brad S. Currier, Stuart M. Phillips
Preservation of skeletal muscle strength, size and function is critical to healthy aging. The progressive loss of each with advancing age—sarcopenia—is deleterious on several levels. Exercise is the primary countermeasure for sarcopenia, but ‘exercise’ alone is a broad recommendation. In a recent publication in the Journal of Cachexia, Sarcopenia and Muscle, Shen and colleagues1 aimed to compare the
-
Small non-coding RNA profiling in patients with gastrointestinal cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-24 Alessio Molfino, Marc Beltrà, Maria Ida Amabile, Roberta Belli, Giovanni Birolo, Elena Belloni, Serena De Lucia, Lorena Garcia-Castillo, Fabio Penna, Giovanni Imbimbo, Giuseppe Nigri, Barbara Pardini, Paola Costelli, Maurizio Muscaritoli
Small non-coding (snc)RNAs, including microRNAs and P-element induced wimpy testis (PIWI)-interacting-RNAs (piRNAs), crucially regulate gene expression in both physiological and pathological conditions. In particular, some muscle-specific microRNAs (myomiRs) have been involved in the pathogenesis of cancer-induced muscle wasting. The aims of the present study were (i) to profile sncRNAs in both skeletal
-
Long-term changes in psoas muscle mass after lobectomy and segmentectomy for early-stage lung cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-23 Tetsuya Isaka, Hiroyuki Ito, Tomoyuki Yokose, Haruhiro Saito, Hiroto Narimatsu, Hiroyuki Adachi, Jun Miura, Kotaro Murakami, Noritake Kikunishi, Naoko Shigeta, Yasushi Rino
Segmentectomy is considered a less invasive procedure than lobectomy for patients with non-small cell lung cancer (NSCLC); however, little is known about the physiological mechanism underlying the lower invasiveness of segmentectomy. This study is aimed to compare the differences in the long-term changes in the psoas muscle mass after segmentectomy and lobectomy in patients with NSCLC.
-
Stimulator of interferon genes promotes diabetic sarcopenia by targeting peroxisome proliferator activated receptors γ degradation and inhibiting fatty acid oxidation J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-21 Sen-bo Yan, Huan Liang, Peng Zhan, Hui Zheng, Qin-xiao Zhao, Zi-jie Zheng, Hui-xia Lu, Guo-kai Shang, Xiao-ping Ji
Declined skeletal muscle mass and function are inevitable consequences of long-term diabetes and bring about many adverse events. Muscle fibre atrophy and interstitial fibrosis are major pathological manifestations of diabetic sarcopenia. Stimulator of interferon genes (STING) participates in various metabolic diseases. We aimed to explore whether and how STING regulates the above pathological manifestations
-
Modelling three-dimensional cancer-associated cachexia and therapy: The molecular basis and therapeutic potential of interleukin-6 transignalling blockade J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-20 Marianna Cosentino, Laura Forcina, Mariam Zouhair, Ludovica Apa, Desirèe Genovese, Caterina Boccia, Emanuele Rizzuto, Antonio Musarò
Causes and mechanisms underlying cancer cachexia are not fully understood, and currently, no therapeutic approaches are available to completely reverse the cachectic phenotype. Interleukin-6 (IL-6) has been extensively described as a key factor in skeletal muscle physiopathology, exerting opposite roles through different signalling pathways.
-
Issue Information J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-24
No abstract is available for this article.
-
Abstracts J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-24
A systemic view of cancer cachexia: Consequences of altered metabolic networks Selma Masri Department of Biological Chemistry, Chao Family Comprehensive Cancer Center, Center for Epigenetics and Metabolism, University of California Irvine, Irvine, CA, USA The circadian clock is the biological mechanism that dictates an array of physiological processes, including sleep/wake cycles, feeding rhythms,
-
Author Index J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-24
A Abbass, Tanvir, 43, 50, 52 Aerts, Hugo J.W.L., 18 Akbari, Masoud, 10 Akin, Oguz, 43 Al Bakir, Maise, 18 Alexander, Peter, 43, 50, 52 Alexeeff, Stacey, 13 Ali, Mona S., 27 Ali, Mona Sadek, 11 Al-Sawaf, Othman, 18 Álvarez, Valentina González, 26 Alyamani, Abdullah, 41 Amano, Koji, 56 Anderson, Lindsey J., 19 Ando, Kenju, 35 Andrews, Zane B., 14 Andrés-Benito, Pol, 28 Angelino, Elia, 14, 19 Annunzio
-
Validity of computed tomography defined body composition as a prognostic factor for functional outcome after kidney transplantation J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-20 Tim D. A. Swaab, Evelien E. Quint, Lisa B. Westenberg, Marcel Zorgdrager, Dorry L. Segev, Mara A. McAdams-DeMarco, Stephan J. L. Bakker, Alain R. Viddeleer, Robert A. Pol
The prevalence of sarcopenia is markedly higher in kidney transplant candidates than in the general population. It is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, which increases the risk of adverse postoperative outcomes.
-
Effects of correcting metabolic acidosis on muscle mass and functionality in chronic kidney disease: a systematic review and meta-analysis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-20 Wesley J. Visser, Elma E.M. van de Braak, Anneke M.E. de Mik - van Egmond, Anna C. van der Burgh, Nicole M. de Roos, Inez Jans, Iris van der Hoef, Joanne F. Olieman, Ewout J. Hoorn, David Severs
Metabolic acidosis unfavourably influences the nutritional status of patients with non-dialysis dependent chronic kidney disease (CKD) including the loss of muscle mass and functionality, but the benefits of correction are uncertain. We investigated the effects of correcting metabolic acidosis on nutritional status in patients with CKD in a systematic review and meta-analysis. A search was conducted
-
Skeletal muscle adaptations in patients with lung cancer: Longitudinal observations from the whole body to cellular level J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-19 Deena B. Snoke, Emma Bellefleur, Hibba Tul Rehman, James A. Carson, Matthew E. Poynter, Kim L. Dittus, Michael J. Toth
Cancer and its treatment can adversely affect skeletal muscle, impacting physical function, treatment response and survival. No studies, however, have comprehensively characterized these muscle adaptations longitudinally in human patients at the cellular level.
-
Effects of sarcopenia and frailty on postoperative recovery in elderly patients: A prospective cohort study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-19 Kedi Guo, Xinghe Wang, Xian Lu, Yuping Yang, Wensi Lu, Shuting Wang, Xihui Tang, Yan Wu, Yuqing Xu, Qingsong Chen, Su Liu
Sarcopenia and frailty are both age-related declines in functional reserve that are linked to adverse health outcomes. It is critical to know about the outcomes of a combination of these conditions. The study aimed to investigate the effects of sarcopenia and frailty on postoperative recovery in elderly patients and to explore risk factors.
-
Increased adipose tissue is associated with improved overall survival, independent of skeletal muscle mass in non-small cell lung cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-19 Junli Tao, Jiayang Fang, Lihua Chen, Changyu Liang, Bohui Chen, Zhenyu Wang, Yongzhong Wu, Jiuquan Zhang
The prognostic significance of non-cancer-related prognostic factors, such as body composition, has gained extensive attention in oncological research. Compared with sarcopenia, the prognostic significance of adipose tissue for overall survival in non-small cell lung cancer remains unclear. We investigated the prognostic value of skeletal muscle and adipose tissue in patients with non-small cell lung
-
Computed tomography-determined skeletal muscle density predicts 3-year mortality in initial-dialysis patients in China J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-18 Ming-jie Sheng, Jing-yuan Cao, Shi-mei Hou, Min Li, Yao Wang, Qiang Fang, A-feng Miao, Min Yang, Shu-su Liu, Chun-hong Hu, Cui-lan Liu, Shi-yuan Wang, Jing Zheng, Jing-jie Xiao, Xiao-liang Zhang, Hong Liu, Bi-cheng Liu, Bin Wang
Skeletal muscle mass and quality assessed by computed tomography (CT) images of the third lumbar vertebra (L3) level have been established as risk factors for poor clinical outcomes in several illnesses, but the relevance for dialysis patients is unclear. A few studies have suggested a correlation between CT-determined skeletal muscle mass and quality at the first lumbar vertebra (L1) level and adverse
-
Bisphosphonates attenuate age-related muscle decline in Caenorhabditis elegans J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-18 Luke Slade, Shelby E. Bollen, Joseph J. Bass, Bethan E. Phillips, Kenneth Smith, Daniel J. Wilkinson, Nathaniel J. Szewczyk, Philip J. Atherton, Timothy Etheridge
Age-related muscle decline (sarcopenia) associates with numerous health risk factors and poor quality of life. Drugs that counter sarcopenia without harmful side effects are lacking, and repurposing existing pharmaceuticals could expedite realistic clinical options. Recent studies suggest bisphosphonates promote muscle health; however, the efficacy of bisphosphonates as an anti-sarcopenic therapy is
-
Abstracts J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-08
1-01 Growth of GL261 glioblastoma tumours induced delayed body weight gain and stunted skeletal muscle growth in paediatric mice Joshua R. Huot1, Nicholas A. Jamnick2, Patrick D. Livingston2, Fabrizio Pin1 and Andrea Bonetto2 1Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, USA; 2Department of Pathology, University of Colorado Anschutz Medical
-
Call for standardization in assessment and reporting of muscle and adipose change using computed tomography analysis in oncology: A scoping review J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-07 Pamela N. Klassen, Vera C. Mazurak, Jessica Thorlakson, Stephane Servais
Investigators are increasingly measuring skeletal muscle (SM) and adipose tissue (AT) change during cancer treatment to understand impact on patient outcomes. Recent meta-analyses have reported high heterogeneity in this literature, representing uncertainty in the resulting estimates. Using the setting of palliative-intent chemotherapy as an exemplar, we aimed to systematically summarize the sources
-
Radiation induces long-term muscle fibrosis and promotes a fibrotic phenotype in fibro-adipogenic progenitors J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-06 Nicolas Collao, Donna D'Souza, Laura Messeiller, Evan Pilon, Jessica Lloyd, Jillian Larkin, Matthew Ngu, Alexanne Cuillerier, Alexander E. Green, Keir J. Menzies, Yan Burelle, Michael De Lisio
Radiation-induced muscle pathology, characterized by muscle atrophy and fibrotic tissue accumulation, is the most common debilitating late effect of therapeutic radiation exposure particularly in juvenile cancer survivors. In healthy muscle, fibro/adipogenic progenitors (FAPs) are required for muscle maintenance and regeneration, while in muscle pathology FAPs are precursors for exacerbated extracellular
-
Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-06 James McDonald, Judith Sayers, Stefan D. Anker, Jann Arends, Trude Balstad, Vickie Baracos, Leo Brown, Asta Bye, Olav Dajani, Ross Dolan, Marie T. Fallon, Eilidh Fraser, Christine Griel, Aleksandra Grzyb, Marianne Hjermstad, Mariam Jamal-Hanjani, Gunnhild Jakobsen, Stein Kaasa, Donald McMillan, Matthew Maddocks, Iain Philips, Inger O. Ottestad, Kieran F. Reid, Mariana S. Sousa, Melanie R. Simpson,
In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be needed alongside other measures. However, it is not clear which physical function endpoints should be used. The aim of this systematic review was to assess the frequency and diversity of physical function endpoints in
-
Caveolin-3 loss linked with the P104L LGMD-1C mutation modulates skeletal muscle mTORC1 signalling and cholesterol homeostasis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-06 Dinesh S. Shah, Raid B. Nisr, Gabriela Krasteva-Christ, Harinder S. Hundal
Caveolins are the principal structural components of plasma membrane caveolae. Dominant pathogenic mutations in the muscle-specific caveolin-3 (Cav3) gene isoform, such as the limb girdle muscular dystrophy type 1C (LGMD-1C) P104L mutation, result in dramatic loss of the Cav3 protein and pathophysiological muscle weakness/wasting. We hypothesize that such muscle degeneration may be linked to disturbances
-
Assessment of the bidirectional causal association between frailty and depression: A Mendelian randomization study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-05 Jiahao Zhu, Dan Zhou, Yaoyao Nie, Jing Wang, Ye Yang, Dingwan Chen, Min Yu, Yingjun Li
Observational studies have demonstrated a strong bidirectional association between frailty and depression, but it remains unclear whether this association reflects causality. This study aimed to examine the bidirectional causal relationship between frailty and depression.
-
Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-05 Hidenori Arai, Keisuke Maeda, Hidetaka Wakabayashi, Tateaki Naito, Masaaki Konishi, Prasert Assantachai, Wai Tung Auyeung, Chalobol Chalermsri, Wei Chen, Justin Chew, Ming-Yueh Chou, Chih-Cheng Hsu, Allyn Hum, In Gyu Hwang, Toshimi Kaido, Lin Kang, Shahrul Bahyah Kamaruzzaman, Miji Kim, Jenny Shun Wah Lee, Wei-Ju Lee, Chih-Kuang Liang, Wee Shiong Lim, Jae-Young Lim, Yen Peng Lim, Raymond See-Kit Lo
Chronic diseases often lead to metabolic disorders, causing anabolic resistance and increased energy consumption, which result in cachexia. Cachexia, in turn, can lead to major clinical consequences such as impaired quality of life, shortened life expectancy, and increased healthcare expenditure. Existing international diagnostic criteria for cachexia employ thresholds derived from Western populations
-
Application of the D3-creatine muscle mass assessment tool to a geriatric weight loss trial: A pilot study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-05 Kristen M. Beavers, Allison E. Avery, Mahalakshmi Shankaran, William J. Evans, S. Delanie Lynch, Caitlyn Dwyer, Marjorie Howard, Daniel P. Beavers, Ashley A. Weaver, Leon Lenchik, Peggy M. Cawthon
Traditionally, weight loss (WL) trials utilize dual energy X-ray absorptiometry (DXA) to measure lean mass. This method assumes lean mass, as the sum of all non-bone and non-fat tissue, is a reasonable proxy for muscle mass. In contrast, the D3-creatine (D3Cr) dilution method directly measures whole body skeletal muscle mass, although this method has yet to be applied in the context of a geriatric
-
Protein intake in cancer: Does it improve nutritional status and/or modify tumour response to chemotherapy? J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-09-04 Martin Boutière, Cécile Cottet-Rousselle, Céline Coppard, Karine Couturier, Catherine Féart, Morgane Couchet, Christelle Corne, Christophe Moinard, Charlotte Breuillard
Combating malnutrition and cachexia is a core challenge in oncology. To limit muscle mass loss, the use of proteins in cancer is encouraged by experts in the field, but it is still debated due to their antagonist effects. Indeed, a high protein intake could preserve lean body mass but may promote tumour growth, whereas a low-protein diet could reduce tumour size but without addressing cachexia. Here
-
Comment on ‘Effects of Vivifrail multicomponent intervention on functional capacity: A multicentre randomized controlled trial’ by Casas-Herrero et al. J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-30 Jin Yan, Tianyi Zhang, Yixin Hu
We read with great interest the recent article by Álvaro Casas-Herrero et al. entitled ‘Effects of Vivifrail multicomponent intervention on functional capacity: a multicentre, randomized controlled trial’.1 The article validated that the Vivifrail multicomponent exercise training programme is an effective and safe intervention for improving functional capacity in community dwelling frail/prefrail older
-
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-17 Sylvia Saalfeld, Robert Kreher, Georg Hille, Uli Niemann, Mattes Hinnerichs, Osman Öcal, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Irene Bargellini, Roberto Iezzi, Thomas Berg, Heinz J. Klümpen, Julia Benckert, Antonio Gasbarrini, Holger Amthauer, Bruno Sangro, Peter Malfertheiner, Bernhard Preim, Jens
Parameters of body composition have prognostic potential in patients with oncologic diseases. The aim of the present study was to analyse the prognostic potential of radiomics-based parameters of the skeletal musculature and adipose tissues in patients with advanced hepatocellular carcinoma (HCC).
-
Prevotella copri alleviates sarcopenia via attenuating muscle mass loss and function decline J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-17 Xiaolei Liu, Jiqiu Wu, Jingyi Tang, Zhigang Xu, Bailing Zhou, Yang Liu, Fengjuan Hu, Gongchang Zhang, Rui Cheng, Xin Xia, Yilong Chen, Hongyu Wu, Daoming Wang, Jirong Yue, Biao Dong, Jingyuan Fu, Haopeng Yu, Birong Dong
The gut microbiome and fecal metabolites have been found to influence sarcopenia, but whether there are potential bacteria that can alleviate sarcopenia has been under-investigated, and the molecular mechanism remains unclear.
-
Frailty and heart failure: State-of-the-art review J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-16 Khawaja M. Talha, Ambarish Pandey, Marat Fudim, Javed Butler, Stefan D. Anker, Muhammad Shahzeb Khan
At least half of all patients with heart failure (HF) are affected by frailty, a syndrome that limits an individual ability to recover from acute stressors. While frailty affects up to 90% of patients with HF with preserved ejection fraction, it is also seen in ~30–60% of patients with HF with reduced ejection fraction, with ~26% higher prevalence in women compared with men. The relationship between
-
A novel splice variant of the human MSTN gene encodes a myostatin-specific myostatin inhibitor J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-15 Kazuhiro Maeta, Manal Farea, Hisahide Nishio, Masafumi Matsuo
Myostatin, encoded by the MSTN gene comprising 3 exons, is a potent negative regulator of skeletal muscle growth. Although a variety of myostatin inhibitors have been invented for increasing muscle mass in muscle wasting diseases, no effective inhibitor is currently available for clinical use. Myostatin isoforms in several animals have been reported to inhibit myostatin, but an isoform has never been
-
Optimization and construct validity of approaches to preclinical grip strength testing J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-13 Gregory Owendoff, Alissa Ray, Prameela Bobbili, Leatha Clark, Cory W. Baumann, Brian C. Clark, W. David Arnold
Background Grip strength is a robust biomarker showing good reliability1, 2 and prediction of negative health outcomes.3, 4 Low grip strength is associated with disability and premature death5-9 and is more strongly associated with frailty than chronological age.10 Accordingly, recent updates to consensus definitions of sarcopenia focus on low grip strength as the primary characteristic as opposed
-
Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-13 Kate T. Murphy, Gordon S. Lynch
There is increasing evidence that neurodegenerative disorders including the Parkinsonian syndromes are associated with impaired skeletal muscle health, manifesting as wasting and weakness. Many of the movement problems, lack of muscle strength and reduction in quality of life that are characteristic of these syndromes can be attributed to impairments in skeletal muscle health, but this concept has
-
A systematic review of automated segmentation of 3D computed-tomography scans for volumetric body composition analysis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-10 Dinh Van Chi Mai, Ioanna Drami, Edward T. Pring, Laura E. Gould, Phillip Lung, Karteek Popuri, Vincent Chow, Mirza F. Beg, Thanos Athanasiou, John T. Jenkins
Automated computed tomography (CT) scan segmentation (labelling of pixels according to tissue type) is now possible. This technique is being adapted to achieve three-dimensional (3D) segmentation of CT scans, opposed to single L3-slice alone. This systematic review evaluates feasibility and accuracy of automated segmentation of 3D CT scans for volumetric body composition (BC) analysis, as well as current
-
The utility of a portable muscle ultrasound in the assessment of muscle alterations in children with acute lymphoblastic leukaemia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-10 Emma J. Verwaaijen, Annelienke M. van Hulst, Jeroen Molinger, Annelies Hartman, Rob Pieters, Martha A. Grootenhuis, Erica L.T. van den Akker, Marry M. van den Heuvel-Eibrink
During treatment for acute lymphoblastic leukaemia (ALL), children are prone to musculoskeletal deterioration. However, non-invasive tools to measure muscle mass and intramuscular alterations are limited. In this study we explored the feasibility of muscle ultrasound in children with ALL. Additionally, we analysed whether automated ultrasound outcomes of muscle size and intramuscular fat infiltration
-
Hispidin-enriched Sanghuangporus sanghuang mycelia SS-MN4 ameliorate disuse atrophy while improving muscle endurance J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-10 I-Chen Li, Ting-Yu Lu, Ting-Wei Lin, Andy Y. Chen, Hsin-Tung Chu, Yen-Lien Chen, Tsung-Ju Li, Chin-Chu Chen
Disuse atrophy is a frequent cause of muscle atrophy, which can occur in individuals of any age who have been inactive for a prolonged period or immobilization. Additionally, acute diseases such as COVID-19 can cause frequent sequelae and exacerbate muscle wasting, leading to additional fatigue symptoms. It is necessary to investigate potent functional nutrients for muscle reinforcement in both disuse
-
Association between the 110-kDa C-terminal agrin fragment and skeletal muscle decline among community-dwelling older women J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-10 Kuniyasu Kamiya, Takahiro Tachiki, Yuho Sato, Katsuyasu Kouda, Etsuko Kajita, Junko Tamaki, Sadanobu Kagamimori, Masayuki Iki
C-terminal agrin fragment (CAF) is a biomarker for neuromuscular junction degradation. This study aimed to investigate whether 110-kDa CAF (CAF110) was associated with the presence and incidence of low muscle mass and strength.
-
One-year change in sarcopenia was associated with cognitive impairment among haemodialysis patients J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-09 Yuqi Yang, Jingjing Da, Jing Yuan, Yan Zha
Our study aimed to evaluate change in sarcopenia, its defining components over 1 year follow-up and investigate associations with subsequent cognitive decline, incident mild cognitive impairment (MCI) and dementia among patients undergoing haemodialysis (HD).
-
Cdon ablation in motor neurons causes age-related motor neuron degeneration and impaired sciatic nerve repair J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-09 Sunghee Kim, Subin An, Jinwoo Lee, Yideul Jeong, Chang-Lim You, Hyebeen Kim, Ju-Hyeon Bae, Chae-Eun Yun, Dongryul Ryu, Gyu-Un Bae, Jong-Sun Kang
The functional deterioration and loss of motor neurons are tightly associated with degenerative motor neuron diseases and aging-related muscle wasting. Motor neuron diseases or aging-related muscle wasting in turn contribute to increased risk of adverse health outcomes in the elderly. Cdon (cell adhesion molecule-downregulated oncogene) belongs to the immunoglobulin superfamily of cell adhesion molecule
-
AAV1.NT-3 gene therapy in the SOD1KO mouse model of accelerated sarcopenia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-08 Lingying Tong, Burcak Ozes, Kyle Moss, Morgan Myers, Alicia Ridgley, Zarife Sahenk
Sarcopenia, an age-related loss of muscle mass, is a critical factor that affects the health of the older adults. The SOD1KO mouse is deficient of Cu/Zn superoxide dismutase, used as an accelerated aging model. We previously showed that NT-3 improves muscle fibre size by activating the mTOR pathway, suggesting a potential for attenuating age-related muscle loss. This study assessed the therapeutic
-
Weight-adjusted waist as an integrated index for fat, muscle and bone health in adults J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-07 Kyoung Jin Kim, Serhim Son, Kyeong Jin Kim, Sin Gon Kim, Nam Hoon Kim
Unhealthy body composition, including high fat mass, low muscle mass and low bone mass, is a critical health issue in adults. The weight-adjusted waist index (WWI) estimates fat and muscle mass and may have implications for bone health. We examined its association with body composition outcomes in a large Korean adult cohort.
-
Comment on: ‘Triceps skinfold-albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al. J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-07 Ping'an Ding, Haotian Wu, Jiaxiang Wu, Chenyu Sun, Muzi Meng, Peigang Yang, Yang Liu, Lingjiao Meng, Qun Zhao
The study by Yin et al.1 is greatly appreciated for their contributions to research, particularly in developing the triceps skinfold-albumin index (TA). This new comprehensive index combines fat mass and nutritional status to evaluate malnutrition and has been identified as independently associated with the prognosis of patients with cancer cachexia. Yin et al.1 successfully identified different cut-off
-
Issue Information J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-08-04
No abstract is available for this article.
-
Underweight status and development of end-stage kidney disease: A nationwide population-based study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-28 Chang Seong Kim, Tae Ryom Oh, Sang Heon Suh, Hong Sang Choi, Eun Hui Bae, Seong Kwon Ma, Bongseong Kim, Kyung-Do Han, Soo Wan Kim
Underweight status increases the risk of cardiovascular disease and mortality in the general population. However, whether underweight status is associated with an increased risk of developing end-stage kidney disease is unknown.
-
Association of malignant ascites with systemic inflammation and muscle loss after treatment in advanced-stage ovarian cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-28 Chia-Sui Weng, Wan-Chun Huang, Chih-Long Chang, Ya-Ting Jan, Tze-Chien Chen, Jie Lee
Malignant ascites is prevalent in advanced-stage ovarian cancer and may facilitate identification of the drivers of muscle loss. This study aimed to evaluate the association of ascites with changes in systemic inflammation and muscle after treatment of advanced-stage ovarian cancer.
-
Comment on 'Hand grip strength-based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer' by Xie et al. J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-28 Ping'an Ding, Jiaxiang Wu, Haotian Wu, Chenyu Sun, Muzi Meng, Scott Lowe, Yuan Tian, Honghai Guo, Lingjiao Meng, Qun Zhao
The study conducted by Xie et al.1 caught our attention, and we extend our gratitude for their valuable contribution. Measuring skeletal muscle index can be costly and tedious. Xie et al. proposed an alternative by using hand grip strength (HGS) to establish a new composite index, HGS-based cachexia index (CXI) (H-CXI), which is calculated as [HGS (kg)/height (m)2 × serum albumin (g/L)]/neutrophil-to-lymphocyte
-
Skeletal muscle-specific DJ-1 ablation-induced atrogenes expression and mitochondrial dysfunction contributing to muscular atrophy J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-19 Shuang Zhang, Hongmei Yan, Jiyang Ding, Ruwen Wang, Yonghao Feng, Xinyi Zhang, Xingyu Kong, Hongyu Gong, Xiaodan Lu, Alice Ma, Yinghui Hua, Huan Liu, Jiani Guo, Huanqing Gao, Zhenqi Zhou, Ru Wang, Peijie Chen, Tiemin Liu, Xingxing Kong
DJ-1 is a causative gene for Parkinson's disease. DJ-1-deficient mice develop gait-associated progressive behavioural abnormalities and hypoactive forearm grip strength. However, underlying activity mechanisms are not fully explored.
-
Associations between indoor air pollution for cooking and heating with muscle and sarcopenia in Chinese older population J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-13 Zhigang Hu, Yufeng Tian, Xinyu Song, Fanjun Zeng, Ailan Yang
Exposure to air pollution brings the advent effect for various diseases, but study about the relationship between air pollution and ageing is scant. We aimed to determine the associations between household air pollution for cooking and heating with muscle and sarcopenia in Chinese older population by a nationally representative study.
-
Impaired proteostatic mechanisms other than decreased protein synthesis limit old skeletal muscle recovery after disuse atrophy J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-14 Jordan D. Fuqua, Marcus M. Lawrence, Zachary R. Hettinger, Agnieszka K. Borowik, Parker L. Brecheen, Marcelina M. Szczygiel, Claire B. Abbott, Frederick F. Peelor, Amy L. Confides, Michael Kinter, Sue C. Bodine, Esther E. Dupont-Versteegden, Benjamin F. Miller
Skeletal muscle mass and strength diminish during periods of disuse but recover upon return to weight bearing in healthy adults but are incomplete in old muscle. Efforts to improve muscle recovery in older individuals commonly aim at increasing myofibrillar protein synthesis via mammalian target of rapamycin (mTOR) stimulation despite evidence demonstrating that old muscle has chronically elevated
-
Corylifol A ameliorates muscle atrophy by inhibiting TAOK1/p38-MAPK/FoxO3 pathway in cancer cachexia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-13 Ruiqin Zhang, Qiang Shen, Yueping Wang, Xue Deng, Jialing Fan, Xiaofan Gu, Meng Fan, Kun Wei, Chun-Ru Cheng, Wei-Dong Zhang, Xiong-wen Zhang, Xuan Liu
Corylifol A (CYA) is one of the main active components of Psoralea corylifolia L. CYA had been reported to have ameliorating effects on dexamethasone-induced atrophy of C2C12 mouse skeletal myotubes, but its effects on cancer cachexia were unclear. Here, we checked the influence of CYA on muscle atrophy in cancer cachexia mice and tried to clarify its mechanisms.
-
Analysis of the rate of force development reveals high neuromuscular fatigability in elderly patients with chronic kidney disease J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-13 Antoine Chatrenet, Giorgina Piccoli, Jean Michel Audebrand, Massimo Torreggiani, Julien Barbieux, Charly Vaillant, Baptiste Morel, Sylvain Durand, Bruno Beaune
Chronic kidney disease (CKD) induces muscle wasting and a reduction in the maximum voluntary force (MVF). Little is known about the neuromuscular fatigability in CKD patients, defined as the reduction of muscle force capacities during exercise. Neuromuscular fatigability is a crucial physical parameter of the daily living. The quantification of explosive force has been shown to be a sensitive means
-
Faecal microbiota transplantation from young rats attenuates age-related sarcopenia revealed by multiomics analysis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-13 Xiaoxing Mo, Lihui Shen, Ruijie Cheng, Pei Wang, Lin Wen, Yunhong Sun, Qiang Wang, Juan Chen, Shan Lin, Yuxiao Liao, Wei Yang, Hong Yan, Liegang Liu
Gut microbiota plays a key role in the development of sarcopenia via the ‘gut-muscle’ axis, and probiotics-based therapy might be a strategy for sarcopenia. Fecal microbiota transplantation from young donors (yFMT) has attracted much attention because of its probiotic function. However, whether or not yFMT is effective for sarcopenia in old recipients is largely unknown. Thus, we aimed to investigate
-
Explainable machine learning model for predicting skeletal muscle loss during surgery and adjuvant chemotherapy in ovarian cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-12 Wen-Han Hsu, Ai-Tung Ko, Chia-Sui Weng, Chih-Long Chang, Ya-Ting Jan, Jhen-Bin Lin, Hung-Ju Chien, Wan-Chun Lin, Fang-Ju Sun, Kun-Pin Wu, Jie Lee
Skeletal muscle loss during treatment is associated with poor survival outcomes in patients with ovarian cancer. Although changes in muscle mass can be assessed on computed tomography (CT) scans, this labour-intensive process can impair its utility in clinical practice. This study aimed to develop a machine learning (ML) model to predict muscle loss based on clinical data and to interpret the ML model
-
Comment on ‘Prediabetes is an independent risk factor for sarcopenia in older men, but not in older women: the Bunkyo Health Study’ by Kaga et al. J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-12 Shanhu Qiu, Xue Cai, Zilin Sun, Tongzhi Wu
We read, with great interest, the recent article by Kaga et al., in which prediabetes was reported to be associated with sarcopenia in older men but not in older women based on the cross-sectional analysis using the baseline data from the Bunkyo Health Study.1 This finding indicates that sarcopenia could have occurred prior to the onset of diabetes, particularly in older men, and highlights the need
-
A single-cell atlas of bovine skeletal muscle reveals mechanisms regulating intramuscular adipogenesis and fibrogenesis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-12 Leshan Wang, Peidong Gao, Chaoyang Li, Qianglin Liu, Zeyang Yao, Yuxia Li, Xujia Zhang, Jiangwen Sun, Constantine Simintiras, Matthew Welborn, Kenneth McMillin, Stephanie Oprescu, Shihuan Kuang, Xing Fu
Intramuscular fat (IMF) and intramuscular connective tissue (IMC) are often seen in human myopathies and are central to beef quality. The mechanisms regulating their accumulation remain poorly understood. Here, we explored the possibility of using beef cattle as a novel model for mechanistic studies of intramuscular adipogenesis and fibrogenesis.
-
Prognostic impact of cachexia by multi-assessment in older adults with heart failure: FRAGILE-HF cohort study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-11 Emi Maekawa, Takumi Noda, Daichi Maeda, Masashi Yamashita, Shota Uchida, Nobuaki Hamazaki, Kohei Nozaki, Hiroshi Saito, Kazuya Saito, Yuki Ogasahara, Masaaki Konishi, Takeshi Kitai, Kentaro Iwata, Kentaro Jujo, Hiroshi Wada, Takatoshi Kasai, Hirofumi Nagamatsu, Tetsuya Ozawa, Katsuya Izawa, Shuhei Yamamoto, Naoki Aizawa, Ryusuke Yonezawa, Kazuhiro Oka, Junya Ako, Shin-ichi Momomura, Nobuyuki Kagiyama
Cachexia substantially impacts the prognosis of patients with heart failure (HF); however, there is no standard method for cachexia diagnosis. This study aimed to investigate the association of Evans's criteria, consisting of multiple assessments, with the prognosis of HF in older adults.
-
Association of intrinsic capacity with incidence and mortality of cardiovascular disease: Prospective study in UK Biobank J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-07-11 Robinson Ramírez-Vélez, Maria Iriarte-Fernández, Guzman Santafé, Armando Malanda, John R. Beard, Antonio Garcia-Hermoso, Mikel Izquierdo
The World Health Organization proposed the concept of intrinsic capacity (IC; the composite of all the physical and mental capacities of the individual) as central for healthy ageing. However, little research has investigated the interaction and joint associations of IC with cardiovascular disease (CVD) incidence and CVD mortality in middle- and older-aged adults.